GlaxoSmithKline plc (LON:GSK) has been given an average recommendation of “Hold” by the eighteen brokerages that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is GBX 1,601.92 ($20.93).
Several equities research analysts have recently weighed in on the stock. Barclays reissued an “equal weight” rating on shares of GlaxoSmithKline in a research report on Wednesday, April 10th. Credit Suisse Group set a GBX 1,600 ($20.91) target price on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Wednesday, April 10th. Deutsche Bank reissued a “hold” rating and issued a GBX 1,520 ($19.86) target price on shares of GlaxoSmithKline in a research report on Friday, April 5th. Shore Capital downgraded shares of GlaxoSmithKline to a “hold” rating in a research report on Friday, January 18th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, March 14th.
In other GlaxoSmithKline news, insider Jesse Goodman purchased 845 shares of the firm’s stock in a transaction dated Wednesday, February 6th. The stock was acquired at an average cost of GBX 1,964 ($25.66) per share, with a total value of £16,595.80 ($21,685.35). Also, insider Emma Walmsley sold 9,053 shares of GlaxoSmithKline stock in a transaction dated Monday, February 18th. The shares were sold at an average price of GBX 1,576 ($20.59), for a total transaction of £142,675.28 ($186,430.52). Insiders bought a total of 3,873 shares of company stock valued at $6,343,952 over the last ninety days.
The firm also recently declared a dividend, which was paid on Thursday, April 11th. Stockholders of record on Thursday, February 21st were issued a GBX 23 ($0.30) dividend. The ex-dividend date of this dividend was Thursday, February 21st. This is a positive change from GlaxoSmithKline’s previous dividend of $19.00. This represents a dividend yield of 1.49%. GlaxoSmithKline’s payout ratio is 1.26%.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Article: NASDAQ
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.